Highlights BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
1.31 ^USD	-4.38%		-11.49%	-24.71%

05-08	BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	CI
04-30	BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	05-08	CI
BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	04-30	CI
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	04-16	DJ
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	04-16	MT
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	04-16	CI
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	04-08	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	02-14	CI
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	02-05	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Biorestorative Therapies Enters into Supply Agreement with Evolutionary Biologics	12/09/23	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
BioRestorative Therapies Secures New York State License to Operate as Tissue Bank	21/07/23	MT
Biorestorative Therapies Inc. Receives License from New York State	21/07/23	CI
BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100	07/07/23	CI
BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program	15/05/23	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial	08/05/23	CI
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100	24/04/23	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Highlights

Filters